We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunofluorescence Assay Market Worth USD 2 Billion by 2023

By LabMedica International staff writers
Posted on 02 Mar 2018
The global immunofluorescence assay market estimated to be worth USD 1.51 billion in 2018 and is projected to grow at a CAGR of 5.8% to reach USD 2.01 billion by 2023, driven by the growing prevalence of chronic diseases, increasing R&D spending, and rise in healthcare spending.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a global market research company.

On the basis of product, the reagents segment held the largest share of the global immunofluorescence assay market due to growing applications of biosciences and biotechnology in the pharmaceutical and healthcare fields, rising prevalence of a number of diseases, increasing R&D activities, and government initiatives to strengthen national research capabilities. On the basis of disease, the cancer segment held the largest share of the immunofluorescence assay market, driven by the increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer.

On the basis of type, the indirect immunofluorescence assay segment held the largest market share, driven by the increasing adoption of the indirect immunofluorescence technique owing to its advantages such as sensitivity, flexibility, better signal amplification, and lower cost than the direct immunofluorescence technique. On the basis of end-user, the pharmaceutical and biotechnology companies segment held the largest share of the immunofluorescence assay market, due to the increasing use of immunofluorescence assay in the study of various diseases and drug discovery & development processes in pharmaceutical and biotechnology companies.

In 2017, North America held the largest share of the global immunofluorescence assay market, followed by Europe and Asia Pacific. The large share of the North American immunofluorescence assay market is mainly due to the rising incidence of chronic & infectious diseases, increasing R&D spending, growing research activities, favorable government funding opportunities, and the presence of key players in the region.

Related Links:
MarketsandMarkets


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Multilevel Whole Blood Calibrator Set
6PLUS1
New
UHF RFID Tag & Inlay
AD-327 U9 ETSI Pure 95

Latest Industry News

AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
01 Mar 2018  |   Industry

Illumina Acquires SomaLogic to Accelerate Proteomics Business
01 Mar 2018  |   Industry

Qiagen and Gencurix Partner on Development of QIAcuity Digital PCR IVD Assay
01 Mar 2018  |   Industry